IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1194 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3682    
    Printed102    
    Emailed2    
    PDF Downloaded262    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 

 CASE REPORT
Year : 2009  |  Volume : 41  |  Issue : 1  |  Page : 47-48

Emergence of pristinamycin resistance in India


1 Department of Pharmacology and Microbiology, Moti Lal Nehru Medical College, Allahabad, Uttar Pradesh, India
2 Department of Pediatrics, Sarojini Naidu Children Hospital, Allahabad, Uttar Pradesh, India

Correspondence Address:
Arun Kumar Kapoor
Department of Pharmacology and Microbiology, Moti Lal Nehru Medical College, Allahabad, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.48884

Rights and Permissions

Quinupristin and dalfopristin combination has been advocated as a drug of choice for multi-drug resistant (MDR) gram-positive cocci (GPC). We are reporting two cases of neonatal septicemia, caused by the methicillin resistant Staphylococcus aureus (MRSA), showing primary in vitro pristinamycin resistance. The Minimum inhibitory concentrations (MIC) for pristinamycin in these two cases were 30 µg and 25 µg, respectively. Universal advocacy of pristinamycin for the therapy of MDR GPC infections should be re-evaluated.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow